Prio Wealth Limited Partnership Grows Stake in Eli Lilly and Company (NYSE:LLY)

Prio Wealth Limited Partnership raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.5% during the third quarter, Holdings Channel reports. The fund owned 2,411 shares of the company’s stock after buying an additional 11 shares during the period. Prio Wealth Limited Partnership’s holdings in Eli Lilly and Company were worth $2,136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Trilogy Capital Inc. boosted its stake in Eli Lilly and Company by 3.9% in the third quarter. Trilogy Capital Inc. now owns 1,347 shares of the company’s stock valued at $1,193,000 after acquiring an additional 51 shares during the last quarter. Penn Davis Mcfarland Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $2,007,000. Calton & Associates Inc. lifted its stake in shares of Eli Lilly and Company by 1,735.7% during the 3rd quarter. Calton & Associates Inc. now owns 19,000 shares of the company’s stock valued at $16,833,000 after buying an additional 17,965 shares in the last quarter. ACT Advisors LLC. lifted its stake in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. ACT Advisors LLC. now owns 278 shares of the company’s stock valued at $246,000 after buying an additional 14 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Eli Lilly and Company by 10.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 408,494 shares of the company’s stock valued at $361,901,000 after buying an additional 39,581 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $6.97 during trading on Monday, reaching $911.00. The company had a trading volume of 362,059 shares, compared to its average volume of 2,971,442. The company has a fifty day moving average of $921.21 and a two-hundred day moving average of $858.60. The stock has a market capitalization of $865.82 billion, a P/E ratio of 134.33, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.